Author

Alessandro Armuzzi

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

Alessandro Armuzzi  et al.

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Alessandro Armuzzi  et al.

Panel discussion: Is it a diverticular disease?
Panel discussion: Is it a diverticular disease?

Alessandro Armuzzi  et al.

ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Alessandro Armuzzi  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS – LIVE STUDY-GROUP

Alessandro Armuzzi  et al.

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi  et al.

TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Alessandro Armuzzi  et al.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

Alessandro Armuzzi  et al.

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Alessandro Armuzzi  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Alessandro Armuzzi  et al.

OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

Alessandro Armuzzi  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

Alessandro Armuzzi  et al.

ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment

Alessandro Armuzzi  et al.

EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Alessandro Armuzzi  et al.

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

Alessandro Armuzzi  et al.

EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN PREDICTING MUCOSAL AND HISTOLOGICAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN PREDICTING MUCOSAL AND HISTOLOGICAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS

Alessandro Armuzzi  et al.

RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN WPAI SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITI
RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN WPAI SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITI

Alessandro Armuzzi  et al.

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES
MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Alessandro Armuzzi  et al.

THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY
THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY

Alessandro Armuzzi  et al.

Item 21 - 40 / 54
1
2
3